Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin.
Female rats bearing N-nitrosomethylurea-induced mammary carcinomas were treated with pergolide mesylate to suppress serum prolactin. The drug was given alone, or with somatostatin, 20 micrograms/hr delivered by osmotic minipump for 7 days to suppress serum growth hormone. Tumour regressions did not occur with pergolide alone, but did so promptly in all of 5 rats when growth hormone levels were also suppressed by somatostatin. A potent long-acting agonistic analogue of somatostatin, L362,823 produced similar tumour regressions at a dose of 5 micrograms/hr when given with pergolide, but was ineffective alone. This dose completely prevented the episodic release of pituitary growth hormone.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000008:administration & dosage; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D007017:Hypophysectomy, Chemical; D008325:Mammary Neoplasms, Experimental / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008770:Methylnitrosourea; D010479:Pergolide; D011388:Prolactin / Q000097:blood*; D051381:Rats; D011919:Rats, Inbred Strains; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives
D004873:Ergolines; D010479:Pergolide; D013004:Somatostatin; D008770:Methylnitrosourea; C026583:cyclo(aminoheptanoic acid-cyclo(cysteinyl-phenylalanyl-D-tryptophyl-lysyl-threonyl-cysteinyl)); D011388:Prolactin; D013006:Growth Hormone